On February 11, for the first time in Georgia and the entire region, robotic ultrasound therapy for prostate cancer — known as Focal One or “RUTH” (Robotic Ultrasound Therapy for HIFU) — was successfully launched at Professor Guram Karazanashvili’s Urology Hub.
Professor Guram Karazanashvili treated the first patients diagnosed with localized prostate cancer using this ultra-modern, non-invasive method. Each procedure lasted only 1–2 hours, and patients were freed from prostate cancer without surgery, radiation, or hormone therapy. The treatments were performed on an outpatient basis, allowing patients to return home the same day — cancer-free!
Focal One (Robotic Ultrasound Therapy, also known as RUTH) represents the most advanced method for the treatment of localized prostate cancer. At the Karazanashvili Robotic Center, this unique, organ-preserving robotic technology opened a new chapter in cancer care — one in which men can defeat prostate cancer while preserving the prostate gland, maintaining sexual function and urinary continence, and leaving the clinic healthy just a few hours later.
It is important to note that Focal One (RUTH), as a non-surgical, non-invasive, radiation-free robotic therapy for prostate cancer, is officially approved by the U.S. Food and Drug Administration (FDA). The FDA is one of the world’s most respected regulatory authorities, ensuring the safety and effectiveness of medications, medical devices, vaccines, and food products for public health.
The Karazanashvili Robotic Center, a global leader in the early diagnosis and treatment of prostate cancer, rightfully holds its place among the world’s leading medical institutions, constantly striving to introduce and implement cutting-edge technologies for the benefit of patients. Today stands as a shining example of that mission.
